Filing Details

Accession Number:
0001968202-24-000122
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-08-19 16:01:37
Reporting Period:
2024-08-15
Accepted Time:
2024-08-19 16:01:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
872589 Regeneron Pharmaceuticals Inc. REGN Pharmaceutical Preparations (2834) 133444607
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1189014 A Christine Poon 777 Old Saw Mill River Road
Tarrytown NY 10591
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-08-15 10,838 $413.33 13,010 No 4 M Direct
Common Stock Disposition 2024-08-15 1,012 $1,155.72 11,998 No 4 S Direct
Common Stock Disposition 2024-08-15 2,368 $1,156.30 9,630 No 4 S Direct
Common Stock Disposition 2024-08-15 1,560 $1,157.33 8,070 No 4 S Direct
Common Stock Disposition 2024-08-15 212 $1,158.02 7,858 No 4 S Direct
Common Stock Disposition 2024-08-15 5,352 $1,159.56 2,506 No 4 S Direct
Common Stock Disposition 2024-08-15 234 $1,160.45 2,272 No 4 S Direct
Common Stock Disposition 2024-08-15 100 $1,161.32 2,172 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2024-08-15 10,838 $0.00 10,838 $413.33
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2025-01-02 No 4 M Direct
Footnotes
  1. Represents volume-weighted average price of sales of 1,012 shares of Company stock on August 15, 2024 at prices ranging from $1,155.38 to $1,155.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.
  2. Represents volume-weighted average price of sales of 2,368 shares of Company stock on August 15, 2024 at prices ranging from $1,156.04 to $1,156.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.
  3. Represents volume-weighted average price of sales of 1,560 shares of Company stock on August 15, 2024 at prices ranging from $1,157.02 to $1,157.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.
  4. Represents volume-weighted average price of sales of 212 shares of Company stock on August 15, 2024 at prices ranging from $1,158.01 to $1,158.08. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.
  5. Represents volume-weighted average price of sales of 5,352 shares of Company stock on August 15, 2024 at prices ranging from $1,159.18 to $1,159.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.
  6. Represents volume-weighted average price of sales of 234 shares of Company stock on August 15, 2024 at prices ranging from $1,160.10 to $1,160.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price.
  7. The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.